We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
MDT expands its sensor lineup, offering more choices alongside Simplera Sync and Guardian 4 sensors.
Medtronic plc (MDT - Free Report) has begun the broad U.S. commercial rollout of the MiniMed 780G system integrated with Abbott’s (ABT - Free Report) Instinct sensor, designed exclusively for MiniMed systems. Earlier this year, the FDA cleared the SmartGuard algorithm as an interoperable automated glycemic controller (iAGC), enabling integration with the Instinct sensor for type 1 diabetes.
The latest development marks a major achievement in diabetes technology and delivers a smart, seamless way to manage diabetes.
MDT Stock’s Likely Trend Following the News
Following the announcement yesterday, MDT shares dropped 1.3%, closing at $102.03. On a promising note, Medtronic’s Diabetes business is in a strong innovation cycle. In the last few months, the MiniMed 780G system received CE Mark for three expanded indications, including for type 2, for children as young as age two and during pregnancy. It also secured U.S. FDA approval for use in adults aged 18 and above, with insulin-requiring type 2 diabetes. Pairing MiniMed 780G with the Instinct sensor further advances the company’s efforts to bring the proven clinical outcomes of the system to more people living with diabetes. Accordingly, the news should help support a rebound in MDT stock performance.
Medtronic has a market capitalization of $132.48 billion at present. Going by the Zacks Consensus Estimate, the company’s fiscal 2026 earnings per share (EPS) are expected to grow 2.9% over 2025. It has delivered an earnings beat of 2.75%, on average, in the trailing four quarters.
More on MDT’s Newest Development
MiniMed 780G is Medtronic's most advanced automated insulin delivery system that automatically adjusts insulin every five minutes based on real-time glucose readings, helping reduce highs and lows, and making diabetes management easier and less time-consuming. Abbott's Instinct sensor is based on its most advanced continuous glucose monitoring (CGM) technology, featuring the world's smallest, thinnest, most discreet sensor. It offers a wear time of up to 15 days.
Image Source: Zacks Investment Research
When paired with the MiniMed 780G system, the Instinct sensor provides real-time glucose readings, which the system uses to automate insulin adjustments every five minutes, helping people with diabetes spend less time managing their condition and more time living their lives.
Additionally, the launch of the Instinct sensor expands Medtronic's sensor portfolio, offering more choice alongside the recently launched Simplera Sync sensor and the Guardian 4 sensor. All are part of a growing ecosystem designed to make diabetes care easier and more personalized.
Industry Prospects Favoring MDT
According to Grand View Research, the global diabetes devices market wasvalued at$30.31 billion in 2023 and is projected to expand at a compound annual growth rate (CAGR) of 7.5% through 2030. Key factors fueling the market’s growth are the growing prevalence of diabetes, advanced technology, increasing usage of insulin delivery devices and the rise in obesity rates.
More Updates From MDT
Medtronic released its fiscal 2026 second-quarter earnings last month, with worldwide revenues of $8.961 billion representing a 6.6% year-over-year increase. The Diabetes business saw particular strength in international markets, which grew 11%. Within the Cardiac Ablation Solutions business, the company gained share as the Pulsed Field Ablation franchise grew more than 300% in the United States as well as in international markets, based on the strength of the Affera mapping system and the Sphere-9 dual energy and high-density mapping catheter.
MDT Stock Price Performance
Year to date, shares of MDT have gained 27.8% compared with the industry’s 3.9% growth.
MDT’s Zacks Rank and Other Top Picks
Medtronic currently carries a Zacks Rank #2 (Buy).
Estimates for Globus Medical’sEPS have increased 11.8% in the past 30 days. Shares of the company have risen 5.5% in the past year against the industry’s 0.6% fall. GMED’s earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 16.2%. In the last reported quarter, it delivered an earnings surprise of 49.4%.
Boston Scientific shares have jumped 9% in the past year. Estimates for the company’s 2025 EPS have increased by 1 cent to $3.04 in the past 30 days. BSX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 7.4%. In the last reported quarter, it posted an earnings surprise of 5.6%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The US Rollout of MiniMed 780G With Abbott's Sensor May Lift MDT Stock
Key Takeaways
Medtronic plc (MDT - Free Report) has begun the broad U.S. commercial rollout of the MiniMed 780G system integrated with Abbott’s (ABT - Free Report) Instinct sensor, designed exclusively for MiniMed systems. Earlier this year, the FDA cleared the SmartGuard algorithm as an interoperable automated glycemic controller (iAGC), enabling integration with the Instinct sensor for type 1 diabetes.
The latest development marks a major achievement in diabetes technology and delivers a smart, seamless way to manage diabetes.
MDT Stock’s Likely Trend Following the News
Following the announcement yesterday, MDT shares dropped 1.3%, closing at $102.03. On a promising note, Medtronic’s Diabetes business is in a strong innovation cycle. In the last few months, the MiniMed 780G system received CE Mark for three expanded indications, including for type 2, for children as young as age two and during pregnancy. It also secured U.S. FDA approval for use in adults aged 18 and above, with insulin-requiring type 2 diabetes. Pairing MiniMed 780G with the Instinct sensor further advances the company’s efforts to bring the proven clinical outcomes of the system to more people living with diabetes. Accordingly, the news should help support a rebound in MDT stock performance.
Medtronic has a market capitalization of $132.48 billion at present. Going by the Zacks Consensus Estimate, the company’s fiscal 2026 earnings per share (EPS) are expected to grow 2.9% over 2025. It has delivered an earnings beat of 2.75%, on average, in the trailing four quarters.
More on MDT’s Newest Development
MiniMed 780G is Medtronic's most advanced automated insulin delivery system that automatically adjusts insulin every five minutes based on real-time glucose readings, helping reduce highs and lows, and making diabetes management easier and less time-consuming. Abbott's Instinct sensor is based on its most advanced continuous glucose monitoring (CGM) technology, featuring the world's smallest, thinnest, most discreet sensor. It offers a wear time of up to 15 days.
Image Source: Zacks Investment Research
When paired with the MiniMed 780G system, the Instinct sensor provides real-time glucose readings, which the system uses to automate insulin adjustments every five minutes, helping people with diabetes spend less time managing their condition and more time living their lives.
Additionally, the launch of the Instinct sensor expands Medtronic's sensor portfolio, offering more choice alongside the recently launched Simplera Sync sensor and the Guardian 4 sensor. All are part of a growing ecosystem designed to make diabetes care easier and more personalized.
Industry Prospects Favoring MDT
According to Grand View Research, the global diabetes devices market wasvalued at$30.31 billion in 2023 and is projected to expand at a compound annual growth rate (CAGR) of 7.5% through 2030. Key factors fueling the market’s growth are the growing prevalence of diabetes, advanced technology, increasing usage of insulin delivery devices and the rise in obesity rates.
More Updates From MDT
Medtronic released its fiscal 2026 second-quarter earnings last month, with worldwide revenues of $8.961 billion representing a 6.6% year-over-year increase. The Diabetes business saw particular strength in international markets, which grew 11%. Within the Cardiac Ablation Solutions business, the company gained share as the Pulsed Field Ablation franchise grew more than 300% in the United States as well as in international markets, based on the strength of the Affera mapping system and the Sphere-9 dual energy and high-density mapping catheter.
MDT Stock Price Performance
Year to date, shares of MDT have gained 27.8% compared with the industry’s 3.9% growth.
MDT’s Zacks Rank and Other Top Picks
Medtronic currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) and Boston Scientific (BSX - Free Report) . While Globus Medical sports a Zacks Rank #1 (Strong Buy), Boston Scientific carries a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Estimates for Globus Medical’sEPS have increased 11.8% in the past 30 days. Shares of the company have risen 5.5% in the past year against the industry’s 0.6% fall. GMED’s earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 16.2%. In the last reported quarter, it delivered an earnings surprise of 49.4%.
Boston Scientific shares have jumped 9% in the past year. Estimates for the company’s 2025 EPS have increased by 1 cent to $3.04 in the past 30 days. BSX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 7.4%. In the last reported quarter, it posted an earnings surprise of 5.6%.